Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
2011

Receptor Tyrosine Kinases as Targets in Rhabdomyosarcoma

publication Evidence: moderate

Author Information

Author(s): Lisa E. S. Crose, Corinne M. Linardic

Primary Institution: Duke University Medical Center

Hypothesis

Targeting receptor tyrosine kinases (RTKs) may improve treatment outcomes for rhabdomyosarcoma (RMS).

Conclusion

Targeting RTKs in RMS shows promise for improving treatment outcomes, especially for high-risk patients.

Supporting Evidence

  • Rhabdomyosarcomas are the most common soft tissue sarcomas in children.
  • Current treatments for high-risk RMS patients are inadequate.
  • RTKs have been identified as druggable targets in RMS.
  • Preclinical studies show that inhibiting RTKs can block tumor growth.

Takeaway

Rhabdomyosarcoma is a type of cancer in kids, and scientists think that blocking certain proteins called RTKs could help treat it better.

Methodology

The review discusses various RTKs implicated in RMS and their potential as therapeutic targets based on preclinical studies.

Limitations

The review does not provide new experimental data but summarizes existing research.

Digital Object Identifier (DOI)

10.1155/2011/756982

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication